UH Seidman discovers newly-approved NSCLC could also treat rare advanced pancreatic cancer

PRECEDE study points to screening method for pancreatic cancer

Research published in April in the Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.

April 19, 2024

Vol.50 No.16

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

In Brief

Anna Berkenblit named chief scientific and medical officer of PanCAN

Anna Berkenblit, a clinical oncologist and drug developer, was named the first-ever chief scientific and medical officer of the Pancreatic Cancer Action Network.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

In Brief

Diane Simeone begins work as director of Moores Cancer Center on April 1

Diane M. Simeone will become director of Moores Cancer Center at UC San Diego Health effective April 1.

March 08, 2024

Vol.50 No.10

Drugs & Targets

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor, or EGFR, exon 20 insertion mutations, as detected by an FDA-approved test.

March 08, 2024

Vol.50 No.10

UH Seidman discovers newly-approved NSCLC could also treat rare advanced pancreatic cancer

YOU MAY BE INTERESTED IN

PRECEDE study points to screening method for pancreatic cancer

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Anna Berkenblit named chief scientific and medical officer of PanCAN

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Diane Simeone begins work as director of Moores Cancer Center on April 1

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

Renew today!

Subscriber content

Login